12.06
Lenz Therapeutics Inc stock is traded at $12.06, with a volume of 711.32K.
It is down -6.94% in the last 24 hours and down -13.67% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$12.96
Open:
$12.78
24h Volume:
711.32K
Relative Volume:
0.69
Market Cap:
$377.36M
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-2.1546
EPS:
-5.5973
Net Cash Flow:
$-73.92M
1W Performance:
-10.80%
1M Performance:
-13.67%
6M Performance:
-71.27%
1Y Performance:
-47.27%
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
LENZ
Lenz Therapeutics Inc
|
12.06 | 405.52M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| Mar-18-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
Presbyopia Pipeline 2026: 10+ Companies, 10+ Emerging Therapies, and 3 Key FDA NDA Milestones Driving the Future of Vision Care, analyses DelveInsight - StreetInsider
LENZ: Strong launch momentum for a new presbyopia eye drop, with robust efficacy and market uptake - TradingView
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Should You Buy LENZ Therapeutics Inc (LENZ) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
LENZ Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Bearish Setup: What are LENZ Therapeutics Incs recent SEC filings showingMarket Activity Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
LENZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Versant Venture Management LLC Buys Shares of 2,656,888 LENZ Therapeutics, Inc. $LENZ - MarketBeat
LENZ Therapeutics to Present at Upcoming Investor Conferences - LENZ Therapeutics
Presbyopia eye-drop firm LENZ lines up two investor conferences - Stock Titan
Risk Check: Can LENZ Therapeutics Inc sustain its profitabilityGold Moves & High Accuracy Swing Trade Signals - baoquankhu1.vn
LENZ Therapeutics (NASDAQ:LENZ) Rating Lowered to Sell at Wall Street Zen - MarketBeat
What’s the beta of LENZ Therapeutics Inc. stockQuarterly Profit Review & Breakout Confirmation Trade Signals - mfd.ru
Breakout Move: What are LENZ Therapeutics Incs recent SEC filings showingWeekly Gains Summary & High Yield Equity Trading Tips - baoquankhu1.vn
Weekly Earnings: Can LENZ Therapeutics Inc reach all time highs this yearMarket Trend Review & Safe Entry Zone Tips - baoquankhu1.vn
LENZ Therapeutics, Inc. $LENZ Shares Acquired by Skandinaviska Enskilda Banken AB publ - MarketBeat
Ridgeback exits Lenz Therapeutics (LENZ) with 0% reported ownership stake - Stock Titan
Short Interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Decreases By 16.8% - MarketBeat
How LENZ Therapeutics Inc. stock compares to market leaders2025 EndofYear Setup & Fast Gain Stock Trading Tips - mfd.ru
LENZ Therapeutics (LENZ) Stock Analysis: Eyeing A 295% Upside In The Biotech Arena - DirectorsTalk Interviews
Analyst Upgrade: Can LENZ Therapeutics Inc disrupt its industryNew Guidance & Consistent Income Trade Recommendations - baoquankhu1.vn
Why is LENZ Therapeutics Inc. stock going upWeekly Stock Report & Reliable Price Action Trade Plans - mfd.ru
Fund Flows: What is the cash position of LENZ Therapeutics IncEarnings Recap Report & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Can LENZ Therapeutics Inc. benefit from deglobalizationJuly 2025 Momentum & Low Risk Growth Stock Ideas - mfd.ru
Is LENZ Therapeutics Inc. stock a value trapBreakout Watch & Advanced Technical Signal Analysis - mfd.ru
Is LENZ Therapeutics Inc. benefiting from interest rate changesWeekly Trading Summary & Low Risk High Win Rate Picks - mfd.ru
Guidance Update: Can LENZ Therapeutics Inc be the next market leaderEarnings Overview Summary & Low Risk Entry Point Tips - baoquankhu1.vn
No Need For Reading Glasses? Vizz Eye Drop That Improves Near Vision Has FDA Nod - MSN
Investment Recap: Why is LENZ Therapeutics Inc stock going upQuarterly Profit Review & Growth Focused Entry Point Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO), LENZ Therapeutics (LENZ) and Amgen (AMGN) - The Globe and Mail
Lenz Therapeutics price target lowered to $35 from $52 at BofA - TipRanks
LENZ Therapeutics stock price target lowered to $35 at BofA on slower ramp - Investing.com Canada
LENZ Therapeutics stock price target lowered to $35 at BofA on slower ramp By Investing.com - Investing.com South Africa
Why Is LENZ Therapeutics Stock Trading Lower Today?LENZ Therapeutics (NASDAQ:LENZ) - Benzinga
What is the cash position of LENZ Therapeutics Inc.July 2025 Closing Moves & Fast Exit Strategy with Risk Control - mfd.ru
Is LENZ Therapeutics Inc. stock a buy or sell2025 Biggest Moves & Precise Buy Zone Tips - mfd.ru
Tenpoint advantage? FDA clears presbyopia duo-drop - bioworld.com
Bull Run: Will LENZ Therapeutics Inc outperform its industry peersJuly 2025 Retail & High Win Rate Trade Tips - baoquankhu1.vn
LENZ Therapeutics and Sarah Jessica Parker Launch ‘Make it VIZZable’ Campaign - VisionMonday.com
In first celebrity partnership, Lenz Therapeutics taps Sarah Jessica Parker for vision campaign - Medical Marketing and Media
Insider Trends: Is Okeanis Eco Tankers Corp a defensive stockEarnings Growth Report & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Sovran Advisors LLC Has $4.98 Million Stock Holdings in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Aug PostEarnings: Why is LENZ Therapeutics Inc stock going up2025 Support & Resistance & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Nasdaq Moves: Why is LENZ Therapeutics Inc stock going upRate Hike & Daily Market Momentum Tracking - baoquankhu1.vn
Trading Action: Is LENZ Therapeutics Inc stock a buy or sellPortfolio Value Summary & Real-Time Volume Spike Alerts - baoquankhu1.vn
LENZ Therapeutics, Inc. (LENZ) Stock Analysis: Unveiling a 155% Potential Upside in Biotechnology - DirectorsTalk Interviews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc.LENZ - PR Newswire
Aug Spikes: What analysts say about LENZ Therapeutics Inc stockPortfolio Return Report & Risk Controlled Daily Plans - baoquankhu1.vn
We're Not Worried About LENZ Therapeutics' (NASDAQ:LENZ) Cash Burn - 富途资讯
Aug Shorts: Why is LENZ Therapeutics Inc stock going upProduct Launch & Weekly Stock Breakout Alerts - baoquankhu1.vn
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lenz Therapeutics Inc Stock (LENZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Olsson Shawn | Chief Commercial Officer |
Nov 17 '25 |
Sale |
26.10 |
10,000 |
261,022 |
4,733 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):